The Library
Development of a model to demonstrate the impact of NICE cost-effectiveness assessment on health utility for targeted medicines
Tools
Tools
Tools
Gallacher, Daniel C., Stallard, Nigel, Kimani, Peter K., Gökalp, Elvan and Branke, Juergen (2021) Development of a model to demonstrate the impact of NICE cost-effectiveness assessment on health utility for targeted medicines. Health Economics . doi:10.1002/hec.4459 (In Press)
|
PDF
WRAP-development-model-demonstrate-the-impact-NICE-cost-effectiveness-assessment-health-utility-targeted-medicines-2021.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (916Kb) | Preview |
|
![[img]](http://wrap.warwick.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
WRAP-development-model-demonstrate-the-impact-NICE-cost-effectiveness-assessment-health-utility-targeted-medicines-2021.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only - Requires a PDF viewer. Download (924Kb) |
Official URL: https://doi.org/10.1002/hec.4459
Abstract
Advances in medical technology have led to a better understanding of heterogeneity of diseases and patients, and to the development of targeted medicines. This development is beneficial to society but can come at an increased cost to pharmaceutical manufacturers due to the costs associated with developing and manufacturing a diagnostic test. For such medicines, the conventional pricing structure, where a therapy is approved if it is deemed cost-effective, may not appropriately incentivise targeted drug development. We model the decision-making processes for both the healthcare provider and the pharmaceutical manufacturer, capturing their main priorities, and populate it with information from a recent appraisal by the National Institute of Health and Care Excellence. Healthcare providers prefer a stratified drug to be developed for a subgroup of the population when the drug is on average effective in the subgroup but with a detrimental effect in the complement. Whilst pharmaceutical manufacturers’ preferences are similar, regions of disagreement exist. We show how preferences can be aligned by either penalising the development of a non-stratified drug or rewarding the development of a stratified drug. The cost and position of alignment depends on the true value of health to the healthcare provider, among other parameters.
| Item Type: | Journal Article | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
||||||||
| Divisions: | Faculty of Social Sciences > Warwick Business School > Operational Research & Management Sciences Faculty of Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) Faculty of Social Sciences > Warwick Business School Faculty of Medicine > Warwick Medical School |
||||||||
| Library of Congress Subject Headings (LCSH): | Medical economics, Medical care, Cost of, Medical informatics, Medical technology -- Cost effectiveness, Medical innovations -- Cost effectiveness | ||||||||
| Journal or Publication Title: | Health Economics | ||||||||
| Publisher: | John Wiley & Sons Ltd. | ||||||||
| ISSN: | 1057-9230 | ||||||||
| Official Date: | 2021 | ||||||||
| Dates: |
|
||||||||
| DOI: | 10.1002/hec.4459 | ||||||||
| Status: | Peer Reviewed | ||||||||
| Publication Status: | In Press | ||||||||
| Access rights to Published version: | Open Access | ||||||||
| RIOXX Funder/Project Grant: |
|
||||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
